Non-alcoholic fatty liver disease (NAFLD) affects an estimated 1 in 3 adults in the UK and is closely associated with obesity and type 2 diabetes. With no approved pharmacological treatment specifically for NAFLD, the potential of Mounjaro (tirzepatide) to address liver health is generating considerable research interest.
Understanding NAFLD and NASH
NAFLD encompasses a spectrum of liver conditions, from simple fat accumulation (steatosis) to the more severe non-alcoholic steatohepatitis (NASH), which involves inflammation and can progress to fibrosis, cirrhosis, and liver failure. Key risk factors include:
- Obesity, particularly central adiposity
- Type 2 diabetes and insulin resistance
- High cholesterol and triglyceride levels
- Metabolic syndrome
What the Research Shows
Data from the SURPASS and SURMOUNT trials included liver-related biomarkers, and the results have been encouraging. Tirzepatide treatment was associated with:
- Significant reductions in liver fat content — imaging studies showed decreases of over 50% in some patients
- Improved liver enzyme levels — ALT and AST levels normalised in many participants
- Reduced markers of liver fibrosis — suggesting potential to slow disease progression
- Decreased inflammatory markers relevant to NASH pathology
A dedicated Phase 2 trial (SYNERGY-NASH) specifically evaluated tirzepatide in patients with biopsy-confirmed NASH and demonstrated significant histological improvement, including resolution of NASH without worsening of fibrosis.
Why This Matters for UK Patients
The British Liver Trust estimates that liver disease is the third leading cause of premature death in the UK. With NAFLD prevalence rising in line with obesity rates, treatments that can address both conditions simultaneously are urgently needed. The NHS currently manages NAFLD primarily through lifestyle advice, making pharmacological options a significant unmet need.
Current Status and Access
Mounjaro is not yet licensed specifically for NAFLD or NASH treatment in the UK. However, patients with fatty liver disease who also qualify for Mounjaro through obesity or diabetes pathways may experience liver-related benefits. If you are concerned about your liver health, request liver function tests and discuss your options with your GP.
Monitoring Your Liver Health
Regular liver function tests are recommended for all patients taking Mounjaro, particularly those with known fatty liver disease. Your healthcare team may also recommend periodic ultrasound or FibroScan assessments to track changes in liver fat and fibrosis. These monitoring tools are widely available through NHS hepatology services.